Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies
- PMID: 23408094
- PMCID: PMC3675753
- DOI: 10.1208/s12248-013-9464-8
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies
Abstract
The industry-wide biopharmaceutical (i.e., biologic, biotherapeutic) pipeline has been growing at an astonishing rate over the last decade with the proportion of approved new biological entities to new chemical entities on the rise. As biopharmaceuticals appear to be growing in complexity in terms of their structure and mechanism of action, so are interpretation, analysis, and prediction of their quantitative pharmacology. We present here a modeling and simulation (M&S) framework for the successful preclinical development of monoclonal antibodies (as an illustrative example of biopharmaceuticals) and discuss M&S strategies for its implementation. Critical activities during early discovery, lead optimization, and the selection of starting doses for the first-in-human study are discussed in the context of pharmacokinetic-pharmacodynamic (PKPD) and M&S. It was shown that these stages of preclinical development are and should be reliant on M&S activities including systems biology (SB), systems pharmacology (SP), and translational pharmacology (TP). SB, SP, and TP provide an integrated and rationalized framework for decision making during the preclinical development phase. In addition, they provide increased target and systems understanding, describe and interpret data generated in vitro and in vivo, predict human PKPD, and provide a rationalized approach to designing the first-in-human study.
Figures



Similar articles
-
Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.AAPS J. 2013 Apr;15(2):354-66. doi: 10.1208/s12248-012-9436-4. Epub 2012 Dec 19. AAPS J. 2013. PMID: 23250669 Free PMC article.
-
On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):195-209. doi: 10.1111/j.1742-7843.2009.00513.x. Epub 2009 Dec 29. Basic Clin Pharmacol Toxicol. 2010. PMID: 20050847 Review.
-
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.AAPS J. 2011 Jun;13(2):169-78. doi: 10.1208/s12248-011-9256-y. Epub 2011 Feb 19. AAPS J. 2011. PMID: 21336535 Free PMC article.
-
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.MAbs. 2013 May-Jun;5(3):373-83. doi: 10.4161/mabs.23826. Epub 2013 Mar 25. MAbs. 2013. PMID: 23529133 Free PMC article.
-
Translational strategies for development of monoclonal antibodies from discovery to the clinic.Drug Discov Today. 2009 Mar;14(5-6):298-305. doi: 10.1016/j.drudis.2008.12.008. Epub 2009 Jan 17. Drug Discov Today. 2009. PMID: 19152840 Review.
Cited by
-
Human FcRn Tissue Expression Profile and Half-Life in PBMCs.Biomolecules. 2019 Aug 15;9(8):373. doi: 10.3390/biom9080373. Biomolecules. 2019. PMID: 31443181 Free PMC article.
-
Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment.J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):141-51. doi: 10.1007/s10928-014-9352-6. Epub 2014 Mar 12. J Pharmacokinet Pharmacodyn. 2014. PMID: 24619141
-
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.AAPS J. 2015 Jul;17(4):828-36. doi: 10.1208/s12248-015-9766-0. Epub 2015 May 2. AAPS J. 2015. PMID: 25933599 Free PMC article. Review.
-
Drug Design and Discovery: Principles and Applications.Molecules. 2017 Feb 13;22(2):279. doi: 10.3390/molecules22020279. Molecules. 2017. PMID: 28208821 Free PMC article.
-
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Protein Cell. 2018 Jan;9(1):15-32. doi: 10.1007/s13238-017-0408-4. Epub 2017 Apr 19. Protein Cell. 2018. PMID: 28421387 Free PMC article. Review.
References
-
- Nagle PC, Nicita CA, Gerdes LA, Schmeichel CJ. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am J Manag Care. 2008;14(4):226–9. - PubMed
-
- Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care. 2003;9(6 Suppl):S124–35. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials